Number of patients | 207 |
---|---|
Age, years (SD) | 75.0 (9.0) |
Men, n (%) | 144 (69.6) |
Women, n (%) | 63 (30.4) |
Diabetes duration, years (SD) | 11.4 (0.8) |
BMI, kg/m2 (SD) | 26.7 (0.6) |
Oral antidiabetic agents, n (%) | 92 (44.4) |
Insulin, n (%) | 152 (73.4) |
High blood pressure, n (%) | 144 (69.6) |
Hypercholesterolemia, n (%) | 113 (54.6) |
Smoking status | |
 Never smoked, n (%) | 57 (27.5) |
 Past smoker, n (%) | 23 (11.1) |
 Current smoker, n (%) | 127 (61.4) |
ABI (SD) | 0.39 (0.07) |
Rutherford staging | |
 Stage 4, n (%) | 112 (54.1) |
 Stage 5, n (%) | 95 (45.9) |
WIfI classification | |
 WIfI 010, n (%) | 63 (30.4) |
 WIfI 020, n (%) | 53 (25.6) |
 WIfI 110, n (%) | 49 (23.7) |
 WIfI 120, n (%) | 42 (20.3) |
Previous coronary artery disease, n (%) | 95 (45.9) |
Previous cerebrovascular disease, n (%) | 101 (48.8) |
Total cholesterol, mg/dL (SD) | 219.3 (22.3) |
LDL cholesterol, mg/dL (SD) | 112.7 (15.5) |
Triglycerides, mg/dL (SD) | 172.4 (8.5) |
Glucose, mg/dL (SD) | 128.0 (9.7) |
HbA1C, % (SD) | 8.9 (0.7) |
eGFR, mL/min/1.73 m2 (SD) | 72.8 (10.6) |
Omentin-1, ng/mL (SD) | 29.2 (5.4) |